PLCG2 and B-cell chronic lymphocytic leukemia: Subsequently, we showed that the first two PLCγ2 point mutants to be described to mediate ibrutinib resistance in CLL, R665W and L845F, are strikingly hypersensitive to activation by Rac [17].